Breaking News Instant updates and real-time market news.

STJ

Acquired by ABT

$79.44

1.78 (2.29%)

, ABT

Abbott

$41.17

0.58 (1.43%)

07:17
10/19/16
10/19
07:17
10/19/16
07:17

St. Jude Medical says 'excited' about Abbott transaction

Commenting on the company's financial results, St. Jude Medical (STJ) President and CEO, Michael T. Rousseau said, "Third quarter results continue to confirm that our innovation based growth strategy is on track. As we continue to establish ourselves as the global technology leader in our markets, our focus is on bringing new technology to patients in the fourth quarter and throughout 2017 that will elevate current standards of care while reducing the cost of healthcare. We also remain excited about the Abbott (ABT) transaction, which we continue to expect to close in the fourth quarter of 2016." As previously announced, St. Jude Medical has changed its sales reporting to more closely align with how the company manages the business in five key areas: atrial fibrillation, heart failure, neuromodulation, cardiovascular and traditional cardiac rhythm management. AF product sales for the third quarter totaled $316 million, a 14 percent increase on a reported basis and a 12 percent increase on a constant currency basis compared to the prior year quarter. HF product sales, which include cardiac resynchronization therapy products, HeartMate ventricular assist devices and the CardioMEMS HF System, totaled $351 million for the third quarter, a 46 percent increase compared to the prior year quarter. St. Jude Medical sales of neuromodulation products were $141 million in the third quarter of 2016, a 17 percent increase on both a reported and constant currency basis compared to the prior year quarter. Total cardiovascular sales were $313 million for the third quarter of 2016, an increase of 8 percent compared to the prior year quarter. Total CRM sales, which include single and dual chamber implantable cardioverter defibrillator and pacemaker products, were $378 million for the third quarter of 2016, a 7 percent decline on both a reported and constant currency basis compared to the third quarter of 2015.

STJ

Acquired by ABT

$79.44

1.78 (2.29%)

ABT

Abbott

$41.17

0.58 (1.43%)

  • 19

    Oct

  • 19

    Oct

  • 21

    Oct

  • 26

    Oct

  • 06

    Nov

STJ Acquired by ABT
$79.44

1.78 (2.29%)

08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
ABT Abbott
$41.17

0.58 (1.43%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.

TODAY'S FREE FLY STORIES

HII

Huntington Ingalls

$222.73

2.25 (1.02%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Hot Stocks
Huntington Ingalls partners with Ivis to develop compliance software »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$40.93

-1.44 (-3.40%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Options
JD options volume is 2.5X daily average and calls outpace puts 4:1 »

JD options volume is 2.5X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$171.00

-8 (-4.47%)

, INTC

Intel

$37.16

-0.02 (-0.05%)

15:42
09/26/17
09/26
15:42
09/26/17
15:42
Periodicals
Breaking Periodicals news story on Nvidia, Intel, Tesla »

Tesla shifting from…

NVDA

Nvidia

$171.00

-8 (-4.47%)

INTC

Intel

$37.16

-0.02 (-0.05%)

TSLA

Tesla

$344.99

-6.1 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

  • 08

    Oct

  • 22

    Oct

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

, TWLO

Twilio

$28.86

-0.615 (-2.09%)

15:38
09/26/17
09/26
15:38
09/26/17
15:38
Hot Stocks
Amazon discussses launch of AWS Global SMS two-way text messaging »

Amazon's (AMZN)…

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

TWLO

Twilio

$28.86

-0.615 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

LNDC

Landec

$11.95

-0.3 (-2.45%)

15:34
09/26/17
09/26
15:34
09/26/17
15:34
Options
Landec options imply 12.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

T

AT&T

$38.80

-0.32 (-0.82%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Periodicals
AT&T's DirecTV to allow 'some' refunds after anthem strife, WSJ says »

Certain subscribers to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Nov

AMJ

American Medical Laboratories Inc

$28.50

0.01 (0.04%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Options
Alerian MLP attracts a bullish option play »

Alerian MLP attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.47

-1.105 (-1.28%)

15:27
09/26/17
09/26
15:27
09/26/17
15:27
Hot Stocks
AbbVie says will take one single digit price increase for 2018 »

AbbVie issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 08

    Nov

STZ

Constellation Brands, also tag STZ.B

$200.37

-0.24 (-0.12%)

15:25
09/26/17
09/26
15:25
09/26/17
15:25
Options
Constellation Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

$NSD

NASDAQ Market Internals

15:17
09/26/17
09/26
15:17
09/26/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
09/26/17
09/26
15:16
09/26/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/26/17
09/26
15:15
09/26/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

AAPL

Apple

$150.55

-1.34 (-0.88%)

, AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

15:08
09/26/17
09/26
15:08
09/26/17
15:08
Periodicals
Apple TV back on Amazon after two-year hiatus, TechCrunch reports »

The Apple (AAPL) TV is…

AAPL

Apple

$150.55

-1.34 (-0.88%)

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

GEC

Great Elm Capital

$3.60

-0.1 (-2.70%)

15:05
09/26/17
09/26
15:05
09/26/17
15:05
Hot Stocks
Breaking Hot Stocks news story on Great Elm Capital  »

Northern Right Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$136.87

0.22 (0.16%)

15:04
09/26/17
09/26
15:04
09/26/17
15:04
Options
Cintas options imply 6.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

LNEGY

Linde

$19.40

-0.31 (-1.57%)

, PX

Praxair

$138.77

1.07 (0.78%)

15:02
09/26/17
09/26
15:02
09/26/17
15:02
Conference/Events
Praxair to host special shareholder meeting »

Special Shareholder…

LNEGY

Linde

$19.40

-0.31 (-1.57%)

PX

Praxair

$138.77

1.07 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ALXN

Alexion

$143.96

1.14 (0.80%)

14:55
09/26/17
09/26
14:55
09/26/17
14:55
Options
Alexion put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 23

    Oct

BXS

BancorpSouth

$31.05

0.3 (0.98%)

14:51
09/26/17
09/26
14:51
09/26/17
14:51
Conference/Events
BancorpSouth to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$34.87

-1.2 (-3.33%)

14:49
09/26/17
09/26
14:49
09/26/17
14:49
Options
Micron options imply 11.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ASND

Ascendis Pharma

$36.13

1.89 (5.52%)

14:48
09/26/17
09/26
14:48
09/26/17
14:48
Recommendations
Ascendis Pharma analyst commentary  »

BofA/Merrill ups Ascendis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$12.17

-0.15 (-1.22%)

14:43
09/26/17
09/26
14:43
09/26/17
14:43
Hot Stocks
Horizon Pharma slides after patent claims ruled unpatentable »

Shares of Horizon Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMD

Psychemedics

$17.43

-0.83 (-4.55%)

14:38
09/26/17
09/26
14:38
09/26/17
14:38
Hot Stocks
Psychemedics announces addition of FDA-cleared Benzodiazepines hair test »

Psychemedics Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$175.67

-1.21 (-0.68%)

14:35
09/26/17
09/26
14:35
09/26/17
14:35
Hot Stocks
Parker-Hannifin down over 1% after U.S anticompetition suit »

Shares of Parker-Hannifin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAA

Under Armour

$16.54

-0.2 (-1.19%)

14:35
09/26/17
09/26
14:35
09/26/17
14:35
Options
Under Armour Class A put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

, GNUS

Genius Brands

$3.64

0.01 (0.28%)

14:33
09/26/17
09/26
14:33
09/26/17
14:33
Conference/Events
Genius Brands to hold an investor update conference call »

Chairman & CEO Heyard…

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

GNUS

Genius Brands

$3.64

0.01 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.